This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BioSante Satisfied to Be Second

BioSante Pharmaceuticals (BPA) is a sexy stock.

The standout opportunity amidst the small drug company's well-stocked pipeline of hormone therapy products is a testosterone gel that, if approved for sale, would be used by menopausal women to boost their flagging sex drive.

The commercial market for legitimate products to treat "female sexual dysfunction" barely exists today. This stands in stark contrast to the mountains of cash forked over by men for drugs like Viagra, Cialis and Levitra.

But gender inequality over sexual dysfunction treatments is about to change, which puts BioSante in a sweet spot. And at a current stock price of $8.91 and a market cap of $164 million, the company is both underappreciated by investors and undervalued given the significant commercial potential for products like LibiGel.

There are a bunch of reasons to like the BioSante story. For starters, there is well-established science behind LibiGel, and with that foundation comes a relatively lower risk that the product blows up. Doctors have long understood that a lower-than-normal level of the hormone testosterone contributes to a waning desire for sex in women, especially women nearing, or in, menopause. When testosterone levels are boosted back to normal levels, a woman's desire for sex also returns to more normal levels.

Pfizer (PFE) spent many years trying to prove that Viagra would also work for women, but while the drug did increase blood flow to the vagina (it does the same for a man's penis), the drug giant found that women who took Viagra did not have an increased desire for sex. This bolstered the belief that hormones play a larger role in female sex drive and forced Pfizer earlier this year to stop testing Viagra for women.

Competitor's Success Bolsters LibiGel

The best evidence of LibiGel's efficacy, so far, actually comes from a larger competitor. Procter & Gamble (PG) is developing Intrinsa, a testosterone patch that treats female sexual dysfunction. In May, the company announced positive results from a pivotal phase III study of 562 women, who had had their ovaries removed and were therefore in menopause. Women in the study who wore the testosterone patch reported a 74% increase in the frequency of satisfying sexual activity as well as a 56% increase in sexual desire vs. baseline. Results from the study were statistically significant, and Procter & Gamble is expected to seek Intrinsa marketing approval from the Food and Drug Administration by the end of the year.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,039.62 -14.09 -0.08%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs